TABLE 4.

Characteristics of Patients With Virologic Rebound (>50 copies/mL) During Open-Label Extension

Patient	Original Treatment Assignment	Integrase Amino Acid Changes From Baseline	Baseline HIV RNA (copies/mL)	Baseline OBT GSS/PSS*	Enfuvirtide Use in OBT
1	600 mg	Q148H, G140S, Q7K/Q, S81R/S, S255N/S/K/R, V280G/V	136,000	0/3	Yes (used before)
2	400 mg	Q148H, G140S	29,800	0/0	Yes (first-time user)
3	200 mg	D279D/N	11,700	0/0	Yes (used before)
4	600 mg	Q148R, E138K	10,900	0/2	No
5	200 mg	T66A, V79V/A, Y143C, E232Q, N155H–(present on different PCR products)	276,000	1/1	No
6	400 mg	Q148R, G140S, E138A	20,700	0/1	No
7†	200 mg		41,400	1/1	No
8†	400 mg		9950	0/2	No
9‡	600 mg		31,300	0/0	Yes (first-time user)

^*GSS/PSS score by PhenoSense GT, enfuvirtide use in OBT is not counted here.

^†Patient’s viral load never returned to above 400 copies/mL and was not tested.

^‡Multiple PCR tests failed.